Terns Pharmaceuticals, Inc.

TERN

Terns Pharmaceuticals, Inc.

TERN

Insider Sentiment (TTM):

Last Purchase:2025-06-27Last Sale:2026-04-01Shares Purchased (TTM):0Shares Sold (TTM):196,815

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:115,573,712Shares Outstanding:93,166,571Institutional Ownership Pct.:124.05%

Earnings Market Reaction:

Filing Date:2026-03-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Cash And Cash Equivalents At Carrying Value	525	151	146	139	161	270	91	65	80	38	81	184
Marketable Securities Current	494	145	169	195	197	103	134	176	184	229	205	113
Assets Current
Assets Current	1,024	300	319	338	362	377	230	246	267	270	288	300
Prepaid Expense And Other Assets Current	5	5	4	3	4	4	5	5	4	4	3	2
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	1	1	1	1
Operating Lease Right Of Use Asset	1	1	1	1	1	1	0	0	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	1,025	302	320	339	364	378	231	247	269	272	290	301
Liabilities And Stockhold…
Accounts Payable Current	2	3	3	3	2	2	2	2	3	3	6	3
Liabilities Current
Liabilities Current	16	15	13	11	16	11	11	9	12	12	14	12
Operating Lease Liability Current	0	0	0	0	0	0	0	0	1	1	1	1
Accrued Income Taxes Noncurrent	2	2	2	2	1	1	1	1	1	1	1	1
Operating Lease Liability Noncurrent	0	1	1	1	1	1	-	-	0	0	0	0
Liabilities	19	18	15	13	18	14	12	10	13	13	16	14
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,524	778	775	771	768	764	597	592	588	571	557	552
Stockholders Equity
Stockholders Equity	1,007	284	305	326	346	364	219	237	255	258	274	288
Accumulated Other Comprehensive Income Loss Net Of…	0	0	-0	0	-0	0	-0	-0	-0	-1	-1	-0
Retained Earnings Accumulated Deficit	-518	-494	-469	-445	-421	-400	-378	-355	-333	-312	-282	-264
Liabilities And Stockholders Equity	1,025	302	320	339	364	378	231	247	269	272	290	301
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	112	88	87	87	87	85	70	65	65	62	61	57
Shares Outstanding	112	88	87	87	87	85	70	65	65	62	61	57

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	3.67%	27.67%	101.67%	14.47%	25.66%	27.80%	53.56%	109.78%	80.96%	0.02%	-	-
2024	21.39%	15.62%	26.66%	4.24%	16.96%	-8.76%	-8.65%	-19.80%	-37.80%	-31.85%	-3.18%	17.83%
2023	0.93%	-30.75%	-43.39%	-23.18%	-28.04%	-27.75%	87.61%	90.99%	42.25%	-19.82%	-18.93%	-10.43%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Liquidity Ratios
Current Ratio	62.41	19.52	24.70	30.89	23.14	32.99	21.02	27.85	22.39	22.38	20.25	24.75
Quick Ratio	62.09	19.21	24.43	30.57	22.89	32.67	20.57	27.26	22.06	22.06	20.06	24.57
Working Capital	1.01B	284.91M	306.04M	326.81M	346.46M	365.09M	219.28M	237.07M	255.49M	258.37M	274.08M	287.56M
Leverage & Debt
Debt to Equity	0.02	0.06	0.05	0.04	0.05	0.04	0.06	0.04	0.05	0.05	0.06	0.05
Debt Ratio	0.02	0.06	0.05	0.04	0.05	0.04	0.05	0.04	0.05	0.05	0.05	0.05
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.03	-1.03	-1.00	-0.99	-1.12	-1.13	-1.29	-1.22	-1.27	-1.19	-1.01	-0.98
Free Cash Flow Per Share TTM	-0.88	-0.85	-0.81	-0.78	-0.88	-0.96	-1.06	-1.02	-0.95	-0.83	-0.73	-0.72
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	8.28%	7.22%	-4.33%	-0.73%	-1.50%	3.60%	33.07%	33.71%	49.49%	44.65%	33.99%	34.60%
EPS Growth (1Y)	-7.60%	-9.01%	-22.21%	-19.26%	-11.72%	-4.77%	27.53%	25.40%	-24.41%	-22.12%	-52.49%	-51.26%
Calculated Values
Free Cash Flow TTM	-82.18M	-77.68M	-74.36M	-71.67M	-70.06M	-74.83M	-79.09M	-75.89M	-67.44M	-59.33M	-52.06M	-50.24M
Net Debt	-524.75M	-150.70M	-145.97M	-139.02M	-161.44M	-270.14M	-91.50M	-65.10M	-79.93M	-37.89M	-80.92M	-184.35M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-01Sale

Owner: Kuriakose, Emil

Title: Chief Medical Officer

Shares: 942

Price/Share: $52.75

Value: $49,690.50

Shares Owned: 105,673

Relationship: Officer

Ownership: Direct

2026-03-16Sale

Owner: Burroughs, Amy L.

Title: Chief Executive Officer

Shares: 14,583

Price/Share: $46.94

Value: $684,526.02

Shares Owned: 288,976

Relationship: Director,Officer

Ownership: Direct

2026-02-17Sale

Owner: Burroughs, Amy L.

Title: Chief Executive Officer

Shares: 14,583

Price/Share: $39.03

Value: $569,174.49

Shares Owned: 288,976

Relationship: Director,Officer

Ownership: Direct

2026-01-15Sale

Owner: Burroughs, Amy L.

Title: Chief Executive Officer

Shares: 68,749

Price/Share: $37.28

Value: $2,562,962.72

Shares Owned: 288,976

Relationship: Director,Officer

Ownership: Direct

2026-01-05Sale

Owner: Burroughs, Amy L.

Title: Chief Executive Officer

Shares: 71,339

Price/Share: $38.10

Value: $2,718,015.90

Shares Owned: 138,976

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-01	Kuriakose, Emil	Officer	Chief Medical Officer	Direct	Sale	942	52.75	$49,690.50	105,673	4
2026-03-16	Burroughs, Amy L.	Director,Officer	Chief Executive Officer	Direct	Sale	14,583	46.94	$684,526.02	288,976	4
2026-02-17	Burroughs, Amy L.	Director,Officer	Chief Executive Officer	Direct	Sale	14,583	39.03	$569,174.49	288,976	4
2026-01-15	Burroughs, Amy L.	Director,Officer	Chief Executive Officer	Direct	Sale	68,749	37.28	$2,562,962.72	288,976	4
2026-01-05	Burroughs, Amy L.	Director,Officer	Chief Executive Officer	Direct	Sale	71,339	38.10	$2,718,015.90	138,976	4
2026-01-02	Kuriakose, Emil	Officer	Chief Medical Officer	Direct	Sale	1,155	38.98	$45,021.90	50,365	4
2025-11-04	Quigley, Jill M.	Director	-	Direct	Sale	24,520	18.00	$441,360.00	0	4
2025-10-01	Kuriakose, Emil	Officer	Chief Medical Officer	Direct	Sale	944	7.85	$7,410.40	51,520	4
2025-07-01	Kuriakose, Emil	Officer	Chief Medical Officer	Direct	Sale	853	4.27	$3,642.31	52,464	4
2025-06-27	Gengos, Andrew	Officer	Chief Financial Officer	Direct	Purchase	10,000	3.93	$39,300.00	25,000	4
2025-06-25	Burroughs, Amy L.	Director,Officer	Chief Executive Officer	Direct	Purchase	23,314	3.87	$90,225.18	47,083	4
2025-06-16	Gengos, Andrew	Officer	Chief Financial Officer	Direct	Purchase	5,000	3.95	$19,750.00	15,000	4
2025-04-01	Kuriakose, Emil	Officer	Chief Medical Officer	Direct	Sale	952	2.49	$2,370.48	53,317	4
2025-01-06	Quigley, Jill M.	Director	-	Direct	Sale	8,760	5.79	$50,720.40	0	4
2025-01-06	Vignola, Mark J.	Officer	Chief Financial Officer	Direct	Sale	9,059	5.80	$52,542.20	74,752	4
2025-01-02	Kuriakose, Emil	Officer	Chief Medical Officer	Direct	Sale	4,481	5.71	$25,586.51	54,269	4
2024-12-05	Burroughs, Amy L.	Director,Officer	Chief Executive Officer	Direct	Purchase	15,450	7.15	$110,467.50	19,099	4
2024-11-30	Jung, Melita Sun	Officer	Chief Business Officer	Direct	Purchase	2,250	5.11	$11,497.50	2,250	4
2024-11-30	Burroughs, Amy L.	Director,Officer	Chief Executive Officer	Direct	Purchase	510	5.11	$2,606.10	19,609	4
2024-09-12	Lu, Hongbo	Director	-	Indirect	Purchase	476,190	10.50	$4,999,995.00	476,190	4
2024-09-10	Vignola, Mark J.	Officer	Chief Financial Officer	Direct	Sale	10,000	11.00	$110,000.00	91,940	4
2024-09-09	Quigley, Jill M.	Director	-	Direct	Sale	17,235	10.00	$172,350.00	15,000	4
2024-08-02	Quigley, Jill M.	Director	-	Direct	Sale	8,857	7.50	$66,427.50	15,000	4
2024-07-16	Gordon, Carl L	Director,TenPercentOwner	-	Indirect	Sale	5,188	10.00	$51,880.00	755,635	4
2024-07-16	Orbimed, Genesis Gp Llc, …	Director,TenPercentOwner	-	Indirect	Sale	5,188	10.00	$51,880.00	755,635	4
2024-07-16	Quigley, Jill M.	Director	-	Direct	Sale	400	10.00	$4,000.00	30,000	4
2024-05-31	Vignola, Mark J.	Officer	Chief Financial Officer	Direct	Purchase	4,791	4.44	$21,272.04	91,940	4
2024-05-31	Yoon, Seokho Bryan	Officer	COO and General Counsel	Direct	Purchase	4,791	4.44	$21,272.04	91,940	4
2024-04-03	Vivo, Opportunity, Llc, V…	TenPercentOwner	-	Indirect	Sale	138,066	6.20	$856,009.20	268,573	4
2023-11-30	Vignola, Mark J.	Officer	Chief Financial Officer	Direct	Purchase	743	3.78	$2,808.54	18,399	4
2023-11-30	Yoon, Seokho Bryan	Officer	COO and General Counsel	Direct	Purchase	743	3.78	$2,808.54	18,399	4
2023-05-31	Vignola, Mark J.	Officer	Chief Financial Officer	Direct	Purchase	9,997	1.41	$14,095.77	17,656	4
2023-05-31	Yoon, Seokho Bryan	Officer	COO and General Counsel	Direct	Purchase	9,997	1.41	$14,095.77	17,656	4
2023-05-31	Sundaram, Senthil Vel	Director,Officer	Chief Executive Officer	Direct	Purchase	2,111	1.41	$2,976.51	9,770	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

124.05%

Inst. Shares: 115,573,712

Shares Outstanding: 93,166,571

2025-12-31

122.38%

Inst. Shares: 114,014,305

Shares Outstanding: 93,166,571

2025-09-30

96.54%

Inst. Shares: 88,529,029

Shares Outstanding: 91,701,529

2025-06-30

90.34%

Inst. Shares: 82,726,322

Shares Outstanding: 91,575,039

2025-03-31

89.95%

Inst. Shares: 82,280,997

Shares Outstanding: 91,473,948

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	115,573,712	93,166,571	124.05%
2025-12-31	114,014,305	93,166,571	122.38%
2025-09-30	88,529,029	91,701,529	96.54%
2025-06-30	82,726,322	91,575,039	90.34%
2025-03-31	82,280,997	91,473,948	89.95%
2024-12-31	83,806,413	79,507,474	105.41%
2024-09-30	76,112,474	77,819,658	97.81%
2024-06-30	65,279,277	74,459,774	87.67%
2024-03-31	62,607,572	74,399,378	84.15%
2023-12-31	63,387,748	71,259,239	88.95%
2023-09-30	60,895,299	71,530,180	85.13%
2023-06-30	57,129,399	71,364,110	80.05%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Terns Pharmaceuticals, Inc. (TERN) — SEC Financial Statements & Analysis

Terns Pharmaceuticals, Inc. (TERN) is a pharmaceutical preparations company, incorporated in DE. Terns Pharmaceuticals, Inc. trades on Nasdaq as: TERN. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Terns Pharmaceuticals, Inc. reported a Debt-to-Equity ratio of 0.02x. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.02x

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Terns Pharmaceuticals, Inc. in?

Terns Pharmaceuticals, Inc. (TERN) operates in the Pharmaceutical Preparations industry.

What exchange does TERN trade on?

Terns Pharmaceuticals, Inc. (TERN) trades on the Nasdaq.

Where is Terns Pharmaceuticals, Inc. incorporated?

Terns Pharmaceuticals, Inc. is incorporated in DE.